Back to the future: the 'old-fashioned' way to new medications for neurodegeneration

Peter T Lansbury1

  • 1Harvard Center for Neurodegeneration and Repair and the Department of Neurology, Harvard Medical School, Center for Neurologic Diseases, Brigham and Women's Hospital, 65 Landsdowne St., Cambridge, Massachusetts 02139, USA. plansbury@rics.bwh.harvard.edu

Nature Medicine
|August 10, 2004
PubMed

Insights

Effective treatments for neurodegenerative diseases like Alzheimer's and Parkinson's are slow to develop. Identifying obstacles in drug discovery for neurodegeneration can accelerate future therapeutic progress.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Neurodegenerative diseases, including Alzheimer's and Parkinson's, are increasingly prevalent.
  • Significant research exists on the causes and pathology of these conditions.

Purpose of the Study:

  • To investigate the reasons behind the slow progress in developing effective treatments for neurodegenerative diseases.
  • To identify obstacles hindering drug discovery in neurodegeneration.
  • To derive lessons for accelerating future therapeutic development.

Main Methods:

  • Analysis of existing research on neurodegenerative diseases.
  • Identification and examination of challenges in neurodegenerative drug discovery.

Main Results:

  • Progress toward effective treatments for neurodegenerative diseases has been notably slow.
  • Several key obstacles impede successful drug discovery in this field.

Conclusions:

  • Understanding the specific challenges in neurodegenerative drug discovery is crucial.
  • Addressing these obstacles can pave the way for accelerated development of novel therapies.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367